In the realm of precision medicine and targeted therapies, the development of highly specific inhibitors is paramount. SBE 13 Hydrochloride exemplifies this principle, acting as a potent and selective inhibitor of Polo-like Kinase 1 (PLK1). This compound, available from NINGBO INNO PHARMCHEM CO.,LTD., is a critical tool for researchers seeking to understand and target specific molecular pathways in disease. This article explores the precision of SBE 13 Hydrochloride and its significance as a pharmaceutical intermediate.

The selectivity of SBE 13 Hydrochloride is a key feature that distinguishes it. Unlike broad-spectrum kinase inhibitors, it primarily targets PLK1, with minimal observed inhibition of other related kinases such as Aurora A, Plk2, and Plk3. This specificity is achieved by binding to the inactive conformation of PLK1, a mechanism that ensures targeted action within cancer cells. For researchers, this means a reduced likelihood of off-target effects, leading to more reliable and interpretable experimental results. Scientists looking to buy SBE 13 Hydrochloride for precise molecular studies can rely on its well-defined inhibitory profile.

The chemical properties of SBE 13 Hydrochloride are also noteworthy. Typically appearing as a white to tan powder, it exhibits solubility in DMSO, a common solvent for biochemical assays. Its molecular formula (C24H28Cl2N2O4) and molecular weight (479.40 g/mol) are well-characterized, ensuring consistency in its application. As a pharmaceutical intermediate, the quality and purity of SBE 13 Hydrochloride are of utmost importance. NINGBO INNO PHARMCHEM CO.,LTD., as a manufacturer in China, adheres to stringent quality control measures to provide researchers with a reliable supply of this compound. The pricing and consistent availability of such intermediates are vital for ongoing research projects.

The targeted action of SBE 13 Hydrochloride has profound implications for targeted therapy development. By inhibiting PLK1, it effectively reduces cancer cell proliferation and promotes apoptosis, offering a dual approach to combating cancer. This precise intervention makes it an ideal candidate for preclinical studies exploring novel therapeutic strategies. The ability to purchase SBE 13 hydrochloride with confidence from NINGBO INNO PHARMCHEM CO.,LTD. supports the advancement of these critical investigations.

In conclusion, SBE 13 Hydrochloride represents a benchmark in targeted therapy research due to its exquisite selectivity for PLK1. Its well-defined chemical properties and proven biological activity make it an indispensable pharmaceutical intermediate for scientists. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying this crucial compound, empowering researchers to explore new frontiers in precision medicine and cancer treatment.